Literature DB >> 17561167

Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma.

Marcos F Dall'Oglio1, Leopoldo Alves Ribeiro-Filho, Alberto A Antunes, Alexandre Crippa, Luciano Nesrallah, Pierre D Gonçalves, Kátia R M Leite, Miguel Srougi.   

Abstract

PURPOSE: The biological behavior and clinical outcome of renal cell carcinoma are difficult to predict. We investigated the prognostic impact of clinicopathological variables to establish a risk stratification model to predict recurrence and survival rates.
MATERIALS AND METHODS: We studied 230 patients with renal cell carcinoma (stages T(1-4) N(x) M(0)) who underwent radical nephrectomy and/or nephron sparing surgery, and were followed for a median of 48 months (range 3 to 140). Univariate and multivariate analyses were performed, and the influence of clinical presentation, histological tumor size, tumor grade, lymph node involvement and microvascular tumor invasion on disease-free and cancer specific survival curves was determined. A composition model based on independent prognostic variables was then created to stratify tumors into low, intermediate and high risk of progression.
RESULTS: The tumor recurrence rate was 17% (39 of 230) and the cancer specific mortality rate was 13% (31 of 230). Multivariate analyses determined that microvascular tumor invasion, tumor grade and tumor size were the only independent prognostic factors. Disease-free survival rates for low, intermediate and high risk tumors were 94.7%, 56.8% and 13.1%, respectively. Cancer specific survival rates were 94.7%, 61.7% and 32.0%, respectively.
CONCLUSIONS: Tumor size, Fuhrman grade and microvascular tumor invasion are strong and independent predictors of survival of patients with renal cell carcinoma. Risk assessment and stratification based on this triad of pathological features may allow better individualization of followup schedules and trials of adjuvant treatment for patients with renal cell carcinoma.

Entities:  

Mesh:

Year:  2007        PMID: 17561167     DOI: 10.1016/j.juro.2007.03.128

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Obesity and microvascular invasion in hepatocellular carcinoma.

Authors:  Abby B Siegel; Shuang Wang; Judith S Jacobson; Dawn L Hershman; Emerson A Lim; Jeanette Yu; Lauren Ferrante; Kalpana M Devaraj; Helen Remotti; Shannon Scrudato; Karim Halazun; Jean Emond; Lorna Dove; Robert S Brown; Alfred I Neugut
Journal:  Cancer Invest       Date:  2010-12       Impact factor: 2.176

2.  The Prognostic Factors for Patients with pT1a Renal Cell Carcinoma.

Authors:  Jong Min Kim; Phil Hyun Song; Hyun Tae Kim; Tong Choon Park
Journal:  Korean J Urol       Date:  2010-04-20

3.  CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma.

Authors:  Walter Henriques da Costa; Rafael Malagoli Rocha; Isabela Werneck da Cunha; Francisco Paula da Fonseca; Gustavo Cardoso Guimaraes; Stenio de Cassio Zequi
Journal:  World J Urol       Date:  2011-10-04       Impact factor: 4.226

4.  Prediction models for clear cell renal cell carcinoma ISUP/WHO grade: comparison between CT radiomics and conventional contrast-enhanced CT.

Authors:  Dong Han; Yong Yu; Nan Yu; Shan Dang; Hongpei Wu; Ren Jialiang; Taiping He
Journal:  Br J Radiol       Date:  2020-08-12       Impact factor: 3.039

Review 5.  Tumor thrombus: incidence, imaging, prognosis and treatment.

Authors:  Keith Bertram Quencer; Tamir Friedman; Rahul Sheth; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 6.  Invasion and metastasis of renal cell carcinoma.

Authors:  Shuji Mikami; Mototsugu Oya; Ryuichi Mizuno; Takeo Kosaka; Ken-ichi Katsube; Yasunori Okada
Journal:  Med Mol Morphol       Date:  2013-11-09       Impact factor: 2.309

7.  [Value of the postoperative Störkel score. Predict disease-free survival of patients with surgically resected renal cell carcinoma].

Authors:  M May; S Brookman-Amissah; S Pflanz; N Knoll; J Roigas; S Gunia; B Hoschke; F Kendel
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

8.  Micro soft tissues visualization based on x-ray phase-contrast imaging.

Authors:  Lu Zhang; Shuqian Luo
Journal:  Open Med Inform J       Date:  2011-07-27

9.  Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.

Authors:  A Kapoor; A Gharajeh; A Sheikh; J Pinthus
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

10.  Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma.

Authors:  L Campbell; B Jasani; K Edwards; M Gumbleton; D F R Griffiths
Journal:  Br J Cancer       Date:  2008-02-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.